| Detected | Trial | Change |
|---|---|---|
| 2026-08-12 | NCT07326709 A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants… · Novartis Pharmaceuticals |
Trial sites expanded: 51 -> 60 locations |
| 2026-08-11 | NCT06444217 Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HD · University Hospital, Angers |
Trial completed |
| 2026-08-11 | NCT06444217 Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HD · University Hospital, Angers |
date change Primary completion moved earlier: 2026-07-23 -> 2025-11-17 |
| 2026-08-11 | NCT06444217 Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HD · University Hospital, Angers |
date change Completion moved earlier: 2028-07-23 -> 2025-11-17 |
| 2026-08-11 | NCT06209515 Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease… · Kuopio University Hospital |
date change Primary completion pushed: 2027-12-31 -> 2029-12-31 |
| 2026-08-11 | NCT06209515 Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease… · Kuopio University Hospital |
date change Completion pushed: 2027-12-31 -> 2029-12-31 |
| 2026-08-11 | NCT05686551 GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen… · Hoffmann-La Roche |
date change Completion moved earlier: 2027-04-01 -> 2026-10-31 |
| 2026-08-08 | NCT07609108 Pridopidine Phase 3 Study in Huntington's Disease · Prilenia |
Recruitment opened |
| 2026-08-08 | NCT07609108 Pridopidine Phase 3 Study in Huntington's Disease · Prilenia |
Trial sites expanded: 0 -> 66 locations |
| 2026-08-06 | NCT04713982 Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease · Vanderbilt University Medical Center |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-08-06 | NCT04713982 Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease · Vanderbilt University Medical Center |
date change Completion pushed: 2026-10-01 -> 2027-10-01 |
| 2026-08-04 | NCT07246941 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of… · Hoffmann-La Roche |
Enrollment closed, study ongoing |
| 2026-07-30 | NCT07326709 A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants… · Novartis Pharmaceuticals |
Trial sites expanded: 41 -> 51 locations |
| 2026-07-29 | NCT06667414 Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene… · Hoffmann-La Roche |
Trial completed |
| 2026-07-29 | NCT06667414 Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene… · Hoffmann-La Roche |
date change Primary completion moved earlier: 2027-02-28 -> 2026-07-03 |
| 2026-07-29 | NCT06667414 Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene… · Hoffmann-La Roche |
date change Completion moved earlier: 2027-02-28 -> 2026-07-03 |
| 2026-07-24 | NCT07537075 An Extension of SKY-0515 in Participants With Huntington's Disease · Skyhawk Therapeutics, Inc. |
Trial sites expanded: 4 -> 10 locations |
| First Posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-05-27 | NCT07609108 Pridopidine Phase 3 Study in Huntington's Disease | Prilenia NEW | Phase 3 |
| 2026-05-22 | NCT07601516 Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With… | Teva Branded Pharmaceutical Products R&D LLC NEW | Phase 4 |
| NCT ID | Title | Sponsor | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07609108 | Pridopidine Phase 3 Study in Huntington's Disease | Prilenia | Recruiting |
| NCT07326709 | A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants… | Novartis Pharmaceuticals | Recruiting |
| NCT06312189 | Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With… | Neurocrine Biosciences | Enrolling by Invitation |
| Phase 2/3 | |||
| NCT07378644 | Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants… | Skyhawk Therapeutics, Inc. | Recruiting |
| NCT06873334 | Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With… | Skyhawk Therapeutics, Inc. | Active, Not Recruiting |
| NCT07537075 | An Extension of SKY-0515 in Participants With Huntington's Disease | Skyhawk Therapeutics, Inc. | Enrolling by Invitation |
| NCT04713982 | Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | Vanderbilt University Medical Center | Active, Not Recruiting |
| Phase 2 | |||
| NCT04478734 | Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Recruiting |
| NCT05509153 | A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin… | Western Sydney Local Health District | Recruiting |
| NCT06853743 | The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside… | Oslo University Hospital | Recruiting |
| NCT06254482 | An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in… | Novartis Pharmaceuticals | Active, Not Recruiting |
| NCT05686551 | GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen… | Hoffmann-La Roche | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05822908 | A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD | Vico Therapeutics B. V. | Recruiting |
| NCT07451613 | Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease | Leslie Thompson | Recruiting |
| NCT06826612 | A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease | Hoffmann-La Roche | Recruiting |
| NCT05243017 | Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease | UniQure Biopharma B.V. | Active, Not Recruiting |
| NCT04120493 | Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest… | UniQure Biopharma B.V. | Active, Not Recruiting |
| NCT07339514 | A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest… | ExoRNA Bioscience | Active, Not Recruiting |
| NCT05541627 | A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest… | AskBio France, SAS, a subsidiary of AskBio Inc. | Active, Not Recruiting |
| Phase 1 | |||
| NCT07536061 | A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's… | Sarepta Therapeutics, Inc. | Recruiting |
| NCT06585449 | A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease | Alnylam Pharmaceuticals | Recruiting |
| NCT07516899 | Mass Balance Study of [14C] LPM3770164 in Healthy Participants | Luye Pharma Group Ltd. | Not Yet Recruiting |
| NCT07246941 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of… | Hoffmann-La Roche | Active, Not Recruiting |
| Early Phase 1 | |||
| NCT06634628 | iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand… | CHDI Foundation, Inc. | Recruiting |
| Not specified | |||
| NCT01574053 | Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort | CHDI Foundation, Inc. | Recruiting |